We’re proud to be part of such a tight-knit community. The more we can stay in touch, the closer we can work together. Click subscribe to receive news and updates about Amylyx.
Efficacy and Pharmacokinetics of Subcutaneous Exendin (9-39) in Patients with Post-Bariatric Hypoglycaemia
Lead Author: Colleen M. Craig, MD
Published: Diabetes, Obesity and Metabolism
Date: February 1, 2018
Clinical Trial Design for a Phase II, Randomized, Placebo-Controlled Trial of AMX0035 in Amyotrophic Lateral Sclerosis (CENTAUR)
Lead Author: Joshua Cohen, Co-CEO and Co-Founder, Amylyx Pharmaceuticals
Published: International Symposium on ALS-MND (MNDA)
Date: December 9, 2017
Evaluation of AMX0035, a Novel Combination Therapy for the Treatment of Neurodegenerative Diseases, in Cellular Models of Friedreich’s Ataxia
Lead Author: Kent L. Leslie
Published: International Ataxia Research Conference
Date: September 29, 2017
AMX0035, a Novel Combination Therapeutic Candidate for Treatment of Primary Mitochondrial Diseases
Lead Author: Kent L. Leslie
Published: United Mitochondrial Disease Foundation Mitochondrial Medicine
Date: June 29, 2017
Critical Role for GLP-1 in Symptomatic Post-Bariatric Hypoglycaemia
Lead Author: Colleen M. Craig, MD
Published: Diabetologia
Date: March 1, 2017
Exendin-(9–39) Corrects Fasting Hypoglycemia in SUR-1–/– Mice by Lowering cAMP in Pancreatic β-Cells and Inhibiting Insulin Secretion
Lead Author: Diva D. De León, MD
Published: Metabolism and Bioenergetics
Date: September 1, 2008
Glucagon-Like Peptide-1 is a Physiological Incretin in Rat
Lead Author: Zhili Wang, PhD
Published: Journal of Clinical Investigation
Date: January 1, 1995
Cloning and Functional Expression of the Human Islet GLP-1 Receptor: Demonstration That Exendin-4 Is an Agonist and Exendin-(9–39) an Antagonist of the Receptor
Lead Author: Bernard Thorens, PhD
Published: Diabetes
Date: November 1, 1993